| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ALK inhibitors for ALK-altered paediatric malignancies
|
Brugieres, Laurence
|
|
|
22 |
12 |
p. 1646-1648
|
artikel
|
| 2 |
Annual Congress of the European Association of Nuclear Medicine 2021
|
Geraldes, Flávia Oliveira
|
|
|
22 |
12 |
p. 1655
|
artikel
|
| 3 |
2021 ASTRO annual meeting
|
Gourd, Katherine
|
|
|
22 |
12 |
p. 1657
|
artikel
|
| 4 |
Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes
|
Thariat, Juliette
|
|
|
22 |
12 |
p. e562-e574
|
artikel
|
| 5 |
Cancer care for children in the Gaza Strip
|
Salman, Zeena
|
|
|
22 |
12 |
p. 1667-1668
|
artikel
|
| 6 |
Cancer care for displaced children from Venezuela
|
Metzger, Monika L
|
|
|
22 |
12 |
p. 1665-1666
|
artikel
|
| 7 |
Cancer care for displaced children in Lebanon
|
Saab, Raya
|
|
|
22 |
12 |
p. 1663-1664
|
artikel
|
| 8 |
Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study
|
de Andrade, Kelvin César
|
|
|
22 |
12 |
p. 1787-1798
|
artikel
|
| 9 |
Carcinogenicity of 1,1,1-trichloroethane and four other industrial chemicals
|
|
|
|
22 |
12 |
p. 1661-1662
|
artikel
|
| 10 |
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
|
Gay, Francesca
|
|
|
22 |
12 |
p. 1705-1720
|
artikel
|
| 11 |
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study
|
Fischer, Matthias
|
|
|
22 |
12 |
p. 1764-1776
|
artikel
|
| 12 |
Correction to Lancet Oncol 2021; 22: 1484–85
|
|
|
|
22 |
12 |
p. e539
|
artikel
|
| 13 |
Correction to Lancet Oncol 2021; 22: 1497–98
|
|
|
|
22 |
12 |
p. e539
|
artikel
|
| 14 |
Correction to Lancet Oncol 2021; 22: 1721–31
|
|
|
|
22 |
12 |
p. e539
|
artikel
|
| 15 |
Daytime versus evening infusions of immune checkpoint inhibitors
|
Lévi, Francis
|
|
|
22 |
12 |
p. 1648-1650
|
artikel
|
| 16 |
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial
|
Tang, Chad
|
|
|
22 |
12 |
p. 1732-1739
|
artikel
|
| 17 |
Diplopia, proptosis, and the pancreas
|
Singh, Anupam Kumar
|
|
|
22 |
12 |
p. e575
|
artikel
|
| 18 |
Educational attainment in displaced children with cancer
|
Wilson, Carlene
|
|
|
22 |
12 |
p. 1650-1652
|
artikel
|
| 19 |
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study
|
Qian, David C
|
|
|
22 |
12 |
p. 1777-1786
|
artikel
|
| 20 |
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
|
Lakhani, Nehal J
|
|
|
22 |
12 |
p. 1740-1751
|
artikel
|
| 21 |
Financial toxicity in cancer care in India: a systematic review
|
Boby, Jeffrey Mathew
|
|
|
22 |
12 |
p. e541-e549
|
artikel
|
| 22 |
Fuel shortage affects cancer care in Haiti
|
Das, Manjulika
|
|
|
22 |
12 |
p. 1660
|
artikel
|
| 23 |
Global cancer research in the post-pandemic world
|
Mukherji, Deborah
|
|
|
22 |
12 |
p. 1652-1654
|
artikel
|
| 24 |
Immunotherapy for cancer treatment during pregnancy
|
Borgers, Jessica S W
|
|
|
22 |
12 |
p. e550-e561
|
artikel
|
| 25 |
Impact of the UK Budget on cancer care and research
|
Gourd, Elizabeth
|
|
|
22 |
12 |
p. 1659
|
artikel
|
| 26 |
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
|
Tawbi, Hussein A
|
|
|
22 |
12 |
p. 1692-1704
|
artikel
|
| 27 |
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
|
Strosberg, Jonathan R
|
|
|
22 |
12 |
p. 1752-1763
|
artikel
|
| 28 |
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
|
Banerjee, Susana
|
|
|
22 |
12 |
p. 1721-1731
|
artikel
|
| 29 |
Mental health care for Filipino patients with cancer
|
Eala, Michelle Ann B
|
|
|
22 |
12 |
p. e531
|
artikel
|
| 30 |
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
|
Oosting, Sjoukje F
|
|
|
22 |
12 |
p. 1681-1691
|
artikel
|
| 31 |
New coalition to harmonise USA–China cancer research and care
|
Gunjur, Ashray
|
|
|
22 |
12 |
p. e540
|
artikel
|
| 32 |
Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care?
|
Magné, Nicolas
|
|
|
22 |
12 |
p. 1644-1645
|
artikel
|
| 33 |
Overall survival results from the NETTER-1 trial in neuroendocrine tumours: an important milestone
|
Virgolini, Irene
|
|
|
22 |
12 |
p. 1645-1646
|
artikel
|
| 34 |
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study
|
Pinato, David J
|
|
|
22 |
12 |
p. 1669-1680
|
artikel
|
| 35 |
Racial disparities in cancer care: can we close the gap?
|
The Lancet Oncology,
|
|
|
22 |
12 |
p. 1643
|
artikel
|
| 36 |
RAMES study: is there really a role for VEGF inhibition in mesothelioma?
|
Porta, Camillo
|
|
|
22 |
12 |
p. e532
|
artikel
|
| 37 |
RAMES study: is there really a role for VEGF inhibition in mesothelioma? – Authors' reply
|
Zucali, Paolo Andrea
|
|
|
22 |
12 |
p. e533
|
artikel
|
| 38 |
Roadmap to deal with toxic chemicals in the USA
|
Das, Manjulika
|
|
|
22 |
12 |
p. 1656
|
artikel
|
| 39 |
SABR for operable stage I non-small-cell lung cancer: comparison to surgery
|
Kashihara, Tairo
|
|
|
22 |
12 |
p. e534
|
artikel
|
| 40 |
SABR for operable stage I non-small-cell lung cancer: comparison to surgery
|
Luo, Meng-Si
|
|
|
22 |
12 |
p. e535
|
artikel
|
| 41 |
SABR for operable stage I non-small-cell lung cancer: comparison to surgery
|
Zhang, Jiaqi
|
|
|
22 |
12 |
p. e536
|
artikel
|
| 42 |
SABR for operable stage I non-small-cell lung cancer: comparison to surgery – Authors' reply
|
Chang, Joe Y
|
|
|
22 |
12 |
p. e537-e538
|
artikel
|
| 43 |
Tobacco industry influence during the COVID-19 pandemic
|
Burki, Talha Khan
|
|
|
22 |
12 |
p. 1658
|
artikel
|
Tijdschrift beschrijving